- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Early Insights from ASCO 2025: Press Briefing Highlights with Clinical Impact
May 26th 2025, 12:00pm
A 2025 ASCO press briefing previewed key advances in breast and lung cancer, HER2 diagnostics, and GLP-1s’ link to reduced cancer risk.
Inavolisib Plus Palbociclib and Fulvestrant Improves OS in PIK3CA-Mutant, HR+/HER2– Breast Cancer
May 22nd 2025, 9:00pm
Inavolisib plus palbociclib and fulvestrant improved OS in PIK3CA-mutant, HR-positive, HER2-negative, endocrine-resistant advanced breast cancer.
First-Line Maintenance Lurbinectedin Plus Atezolizumab Boosts Survival in ES-SCLC
May 22nd 2025, 9:00pm
IMforte data highlight potential for lurbinectedin plus atezolizumab to become a new SOC for first-line maintenance treatment in ES-SCLC.
AI-Assisted Training Improves IHC Interpretation, Classification of HER2-Low and HER2-Ultralow Breast Cancer
May 22nd 2025, 9:00pm
AI-assisted training of pathologists enhanced the accuracy of HER2 IHC scoring, potentially expanding eligibility for HER2-targeted treatments.
GLP-1 Agonists Are Linked to Modest Decrease in Obesity-Related Cancers in Adults With Diabetes
May 22nd 2025, 9:00pm
The use of GLP-1 agonists was not associated with higher cancer rates and led to a decrease in obesity-related cancers in adults with diabetes.
Key Takeaways From ASH 2024
May 22nd 2025, 12:05pm
Unpacking Key Data from ASH 2024
Panelists discuss how insights from ASH 2024 highlight emerging trends in treating hematologic malignancies, including advances in targeted therapies, immunotherapies, and personalized medicine to improve patient outcomes.
Experts Spotlight Noteworthy GU Cancer Abstracts Ahead of the 2025 ASCO Annual Meeting
May 22nd 2025, 12:00pm
Ahead of the 2025 ASCO Annual Meeting, experts in genitourinary cancers share the most anticipated research being presented during the meeting.
Insights From Augmented Hyper-CVAD (AHCVAD), a Pediatric-Inspired Regimen for Adults Younger Than 50 Years With ALL
May 22nd 2025, 12:00pm
Unpacking Key Data from ASH 2024
Panelists discuss how the Augmented Hyper-CVAD (AHCVAD) regimen, when applied to adults younger than 50 years with acute lymphoblastic leukemia, demonstrates promising clinical outcomes that challenge conventional age-stratified treatment approaches by achieving high minimal residual disease (MRD) negativity rates and favorable 3-year overall survival, regardless of whether patients undergo allogeneic stem cell transplantation.
Gastrointestinal Cancer Experts Spotlight the Most Exciting Abstracts Ahead of the 2025 ASCO Annual Meeting
May 21st 2025, 12:00pm
Ahead of the 2025 ASCO Annual Meeting, experts in gastrointestinal cancers provide their top anticipated studies they will be watching for at the meeting.
Experts Preview Key Presentations to Watch in Gynecologic Oncology at ASCO 2025
May 20th 2025, 12:00pm
Experts highlight key abstracts and presentations to keep an eye on in gynecologic oncology at the 2025 ASCO Annual Meeting.
postMONARCH ctDNA Analysis Underscores Benefit of Abemaciclib Plus Fulvestrant in HR+ Advanced Breast Cancer
May 19th 2025, 7:00pm
An exploratory ctDNA analysis from postMONARCH highlighted the benefit of abemaciclib plus fulvestrant across HR-positive breast cancer subgroups.
Tucatinib/Trastuzumab Yields Durable Responses in HER2-Mutated Metastatic Breast Cancer
May 19th 2025, 1:00pm
Final analysis of SGNTUC-019 showed a 41.9% ORR, an 80.6% DCR, and a 18.2-month DOR with tucatinib/trastuzumab in pretreated, HER2-mutated metastatic breast cancer.
T-DM1 Plus Palbociclib Displays Activity in HER2+ Metastatic Breast Cancer
May 16th 2025, 10:17pm
T-DM1 plus palbociclib showed significant PFS in patients with HER2-positive metastatic breast cancer.
EL1SSAR Data Shed Light on Leveraging Atezolizumab Plus Nab-Paclitaxel in PD-L1+ TNBC
May 16th 2025, 10:09pm
EL1SSAR data reinforce the importance of PD-L1 assessment to select patients with TNBC with the best outcomes on atezolizumab.
Pretreatment ctDNA Status Is Associated With Distant Recurrent-Free Survival in Early Breast Cancer
May 16th 2025, 10:01pm
Baseline ctDNA concentration was shown to be the most significant predictor of distant recurrence-free survival in patients with early breast cancer.
Zanidatamab/Chemotherapy Yields Responses and Is Safe in HER2-Expressing Metastatic Breast Cancer
May 16th 2025, 9:45pm
Zanidatamab/chemotherapy showed early antitumor activity with a manageable safety profile in patients with HER2-expressing metastatic breast cancer.
Durvalumab Plus Tremelimumab and Trastuzumab Yields Clinical Activity in Trastuzumab-Resistant HER2+ Breast Cancer
May 16th 2025, 8:28pm
Durvalumab plus tremelimumab and trastuzumab produced responses in trastuzumab-resistant, HER2-positive advanced breast cancer.
Neoadjuvant Letrozole/Entrectinib Shows Limited Activity in Invasive Lobular Breast Cancer
May 16th 2025, 6:40pm
Frontline endocrine therapy plus entrectinib failed to decrease RCB to 0/1 in patients with invasive lobular breast carcinoma.
Iza-Bren Shows Preliminary Efficacy, Safety in Heavily Pretreated HER2–/HER2-low Breast Cancer
May 16th 2025, 4:41pm
Iza-bren was safe and displayed early clinical activity in patients with heavily pretreated breast cancer across both HER2-low and HER2-negative subgroups.
Analysis of PADA-1 Trial Highlights Kinetics and Determinants of ESR1 Mutations in HR+/HER2– Metastatic Breast Cancer
May 16th 2025, 12:51pm
An analysis from PADA-1 showed the emergence of ESR1 mutations was uneven over time in hormone receptor–positive, HER2-negative metastatic breast cancer.